Health Blog

Tips | Recommendations | Reviews

How expensive is mavyret treatment medication pricing on insurance?

how expensive is mavyret treatment medication pricing on insurance
If you are concerned about the price of MAVYRET, you have choices. – * Cure is defined as no detectable hep C virus in the blood three months after therapy finishes. Individual outcomes might vary. As of January 2022, the advertised price, also known as the Wholesale Acquisition Cost (WAC), for one month of MAVYRET is $13,200.00.

If you have: You could pay:
$ 20
Medicaid $ 20 $20.00 or less per month, depending on state plan
Commercial Insurance (usually provided by employer) (Blue Cross Blue Shield, Aetna, etc) As little as $5 a month with MAVYRET Savings Card
Medicare: Part D $660.00-3,081.00 per month, depending on coverage phase Most Medicare patients have Standard Part D prescription coverage, which has different costs depending on deductibles and coverage gaps. An Insurance Specialist can help you understand what these costs mean to you, by calling 1-877-628-9738, Monthly out-of-pocket cost for MAVYRET may vary depending on patient’s other medication costs.
Medicare: Low-Income Subsidy (LIS) $9.85 per month starting January 1, 2022
Uninsured or having difficulty paying for your medication myAbbVie Assist provides AbbVie medicines to qualifying patients. Visit AbbVie.com/myAbbVieAssist or call 1-800-222-6885 to learn more.
Other Insurance (VA, DOD, TRICARE, others) Because coverage varies by plan, call 1-877-628-9738 to speak to an Insurance Specialist to find out how much MAVYRET will cost you.
*Important Details About Understanding Your Individual Costs: The chart above provides cost information based on what a person with the type of coverage listed may pay for a 4-week supply of MAVYRET. Your type of health or prescription insurance plan will determine exactly how much you will pay.

How long is the MAVYRET therapy for hepatitis C?

The FDA has approved Mavyret for the treatment of Hepatitis C. For Immediate Release: August 3, 2017 FDA officially authorized Mavyret (glecaprevir and pibrentasvir) to treat individuals with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe renal impairment and those on dialysis.

  1. Mavyret is also authorized for adult patients with HCV genotype 1 infection who have previously been treated with either an NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
  2. Mavyret is the first eight-week therapy authorized for all HCV genotypes 1 through 6 in previously untreated adult patients without cirrhosis.

Historically, the standard treatment duration was at least 12 weeks. “This approval provides a shorter treatment duration for many patients, as well as a treatment option for certain patients with genotype 1 infection, the most prevalent HCV genotype in the United States, who have not been successfully treated with other direct-acting antiviral treatments in the past,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.

Hepatitis C is a viral infection that leads to inflammation of the liver, which can result in impaired liver function or liver failure. The Centers for Disease Control and Prevention estimate that between 2.7 and 3.9 million individuals in the United States have chronic HCV. Some people with chronic HCV infection over many years may experience jaundice (yellowing of the eyes or skin) and consequences like as bleeding, abdominal fluid buildup, infections, liver cancer, and death.

There are at least six HCV genotypes or strains, which are genetically separate viral groupings. Having knowledge of the virus’s strain can influence therapy recommendations. Approximately 75% of Americans infected with HCV have genotype 1, 20-25% have genotypes 2 or 3, and a tiny percentage have genotypes 4, 5, or 6.

  1. Approximately 2,300 persons with HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with moderate cirrhosis participated in clinical studies to examine the safety and effectiveness of Mavyret.
  2. The results of clinical studies revealed that 92-100 percent of patients who got Mavyret for eight, twelve, or sixteen weeks had no detectable virus in their blood 12 weeks after completing therapy, indicating that the patients were cured.

The length of Mavyret therapy varies based on prior treatment, viral genotype, and cirrhosis status. Headaches, weariness, and nausea were the most prevalent adverse events reported by Mavyret patients. Mavyret is contraindicated in persons with severe cirrhosis and is not advised for patients with intermediate cirrhosis.

Additionally, it is contraindicated in people taking atazanavir and rifampin. Hepatitis B virus (HBV) reactivation has been recorded in HCV/HBV coinfected adult patients taking HCV direct-acting antivirals but not HBV antiviral therapy. In certain individuals treated with direct-acting antiviral medications, HBV reactivation can lead to severe liver issues or death.

Before initiating therapy with Mavyret, healthcare practitioners should test all patients for evidence of current or past HBV infection. The FDA approved this request and designations. AbbVie Inc. was given permission for Mavyret by the FDA. The FDA, an organization under the U.S.

High cost of Hep C drug a barrier to treatment

However, hepatitis C treatment is often covered by insurance. Thus, insurance will be the most cost-effective option for many individuals. You may still be subject to limitations, such as prior permission or step treatment, in order to obtain your desired prescription.

Are hep C medications costly?

– The cost of hepatitis C treatment varies according on the type of medicine used. However, the price range for an 8- to 12-week course is $54,000 to $95,000 (or higher). A 12-week prescription of Zepatier, for instance, can cost up to $54,600, while a 12-week course of Harvoni can cost up to $94,500.

Adblock
detector